10x Genomics Inc - Class A
Research 10x Genomics Inc - Class A (TXG) on Bullrun: market cap USD 10.51B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTXG
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Devices
- CurrencyUSD
- Market capUSD 10.51B
- Financial periodQ2 2026
- RevenueUSD 151.04M
- Net income-USD 17.93M
- Free cash flowUSD 15.39M
- Gross margin74.5%
Valuation Snapshot
latest market cap is USD 10.51B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 642.82M | -USD 43.50M | USD 130.12M | 69.1% | -0.35 | USD 473.97M | USD 84.36M | USD 796.33M |
| FY2024 | USD 610.79M | -USD 182.60M | -USD 5.73M | 67.9% | -1.52 | USD 344.07M | USD 82.61M | USD 710.13M |
| FY2023 | USD 618.73M | -USD 255.10M | -USD 63.80M | 66.2% | -2.18 | USD 359.28M | USD 95.37M | USD 741.04M |
| FY2022 | USD 516.41M | -USD 166.00M | -USD 165.27M | 76.7% | -1.46 | USD 219.75M | USD 95.18M | USD 805.74M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 10.51B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 2.08B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.76B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 6.61B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 4.17B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 16.76B | n/a | n/a | n/a |
About 10x Genomics Inc - Class A
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments;
ETFs that hold 10x Genomics Inc - Class A
10x Genomics Inc - Class A is one of the ten largest holdings of 4 ETFs that investors in Europe can buy, most traded first:
| ETF | Weight | TER |
|---|---|---|
| ARK Genomic | 7.96% | 0.75% |
| Global X Genomics & Biotechnology UCITS ETF USD Acc | 5.49% | 0.50% |
| ARK Innovation UCITS ETF Class A USD Accumulation | 4.21% | 0.75% |
| WisdomTree BioRevolution UCITS ETF - USD Acc | 2.64% | 0.45% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 10x Genomics Inc - Class A's market cap?
10x Genomics Inc - Class A's market capitalization is USD 10.51B.
What does 10x Genomics Inc - Class A do?
10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits.